High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Trial ID or NCT#
NCT00186238
Status
NOT RECRUITING
Purpose
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Official Title
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Eligibility Criteria
Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - received cytoreduction prior to transplant - adequate organ function
Exclusion Criteria:
- - previous transplant - smoldering MM or benign monoclonal gammopathy
Investigator(s)
Sally Arai
Blood and marrow transplant specialist,
Hematologist,
Blood and marrow transplant specialist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Laura Johnston
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Medical oncologist,
Hematologist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Negrin
Blood and marrow transplant specialist,
Hematologist,
Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Contact us to find out if this trial is right for you.
Contact
BMT Referrals
6507230822
View on ClinicalTrials.gov
